Ovarian Cancer

Early Findings Demonstrate Efficacy and Safety of PSC-833 and Paclitaxel

Published in Cancer Weekly, June 2nd, 1997

The investigational therapy of PSC-833 combined with paclitaxel, approved for therapy after first-line or subsequent therapy in treating ovarian cancer, has been shown to be safe, tolerable, and can result in renewed paclitaxel responses in patients with paclitaxel- refractory advanced ovarian cancer.

The preliminary findings were reported by Abbie L. Fields, M.D., Assistant Professor of Obstetrics and Gynecology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, at the annual meeting of the American Society of Clinical Oncology (ASCO) in Denver, Colorado.

Four leading New York City medical centers are involved in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-06-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry